This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 1 of 1 for:    NCT00747812
Previous Study | Return to List | Next Study

Study of Occipital Nerve Stimulation for Drug Refractory Migraine (PRISM UK)

This study has been terminated.
(Sponsor closed enrollment early based on interim data from the PRISM US Pivotal Study.)
Information provided by (Responsible Party):
Boston Scientific Corporation Identifier:
First received: September 4, 2008
Last updated: June 28, 2012
Last verified: June 2012
The purpose of this study is to evaluate the safety and effectiveness of an implantable device to treat migraine. There are a significant number of patients who have drug refractory migraine and alternative therapies are needed.

Condition Intervention Phase
Migraine Device: Precision Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Occipital Nerve Stimulation for Drug Refractory Migraine

Resource links provided by NLM:

Further study details as provided by Boston Scientific Corporation:

Primary Outcome Measures:
  • Number of Hours of Headache [ Time Frame: 12 weeks ]
  • Number of Days With 4 or More Hours of Headache [ Time Frame: 12 Weeks ]

Enrollment: 11
Study Start Date: May 2006
Study Completion Date: May 2012
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Stimulation on from activation to 12 weeks post-activation. Stimulation off from 12 weeks post-activation to 16 weeks post-activation. Stimulation on from 16 weeks post-activation to end of study.
Device: Precision
Implantable Neurostimulator
Sham Comparator: 2
Sham Stimulation from activation of device to 12 weeks post-activation. Stimulation on from 12 weeks post-activation on.
Device: Precision
Implantable Neurostimulator


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Be diagnosed with multiple migraines per month of moderate to severe intensity;
  • Be refractory to medication;
  • Be an appropriate candidate for the surgical procedures required fo this study;
  • Be willing and able to comply with all study related procedures;
  • Be capable of reading and understanding patient information materials and giving written informed consent.

Exclusion Criteria:

  • Have onset of headache after age 50;
  • Are current substance abusers (including alcohol and illicit drugs);
  • Have a significant psychiatric disorder;
  • Have previously been treated with occipital nerve stimulation (either temporary trial or permanent implant);
  • Have had nerve stimulation for pain relief.
  • Have had an injection of botulinum toxin in the head or neck within 6 months prior to enrollment;
  • Have previously undergone destructive ganglionectomy affecting C2/C3 occipital and/or trigeminal distribution or have an occipital blockade or radiofrequency procedure currently in effect.
  • Have a condition currently requiring or likely to require the use of MRI or diathermy;
  • Have an active implantable device;
  • Are pregnant or lactating or planning to become pregnant in the next 14 months;
  • Have participated in any drug or device trial in the last 4 weeks or plant to participate in any other study during the next 14 months.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00747812

United Kingdom
Royal Free Hospital - Dept of Clinical Neurosciences
London, United Kingdom, NW3 2QG
Sponsors and Collaborators
Boston Scientific Corporation
Principal Investigator: Peter J. Goadsby, MD Royal Free Hospital NHS Foundation Trust
  More Information

Responsible Party: Boston Scientific Corporation Identifier: NCT00747812     History of Changes
Other Study ID Numbers: PRISM-UK-05
Study First Received: September 4, 2008
Results First Received: June 28, 2012
Last Updated: June 28, 2012

Keywords provided by Boston Scientific Corporation:

Additional relevant MeSH terms:
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases processed this record on September 20, 2017